Legato Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Legato Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,074	Closed	-$867K	–	627
2023 Q1	$867K	Sell	8,074 -1,557	-16%	-$179K	0.16%	229
2022 Q4	$1.06M	Buy	+9,631	New	+$625K	0.2%	166

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Legato Capital Management's RXDX Position: Q2 2023 in Review

Legato Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 8,074 shares — an estimated $867K sold.

Legato Capital Management first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $1.06M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Legato Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Legato Capital Management sold 8,074 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $867K.
Legato Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Legato Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $1.06M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Legato Capital Management's 13F filing for Q2 2023, filed 18 Aug 2023.